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Running Title:
GCC in Colon Carcinomas

Abstract
Guanylyl cyclase C (GCC) a receptor for bacterial diarrheagenic enterotoxins is
expressed selectively by intestinal epithelium and is an endogenous downstream target of
CDX2. The expression of GCC is preserved throughout the adenoma/carcinoma sequence
in the colorectum. Detection of GCC expression by RT-PCR is currently being validated
as a technique to identify occult lymph node metastases in patients with colorectal cancer
(CRC) and for circulating cells in the blood for postoperative surveillance. Although
GCC is widely expressed by well-differentiated CRC its expression in poorly
differentiated CRC has not been evaluated. A tissue microarray was created from 72
archival specimens including 44 poorly differentiated (PDC), 15 undifferentiated or
medullary (MC), 10 signet ring cell (SRC) and 3 neuroendocrine (NE) CRCs. Matched
normal colonic mucosa was used as a positive control. Immunohistochemical staining for
GCC and CDX2 was evaluated as positive or negative based on at least a 10% extent of
staining. Out of the 72 tumor samples 75%, 47%, 90% and 67% of the PDC, MC, SRC
and NE tumors were positive for GCC and 75%, 40%, 90% and 100% of these subsets

were positive for CDX2 respectively. There was excellent correlation between GCC and
CDX2 expression on a case per case basis (p<0.0001). Immunopositivity for GCC was
greater than 95% in a separately stained microarray series of well/moderately
differentiated CRCs. In conclusion, GCC expression is lost in a quarter of poorly
differentiated and half of undifferentiated CRC. Therefore the utility of GCC expression
as a diagnostic and prognostic marker for CRC may be questionable in poorly
differentiated colorectal neoplasms.
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Introduction
Colorectal carcinoma (CRC) is the third most common cause of cancer death in
the United States.1 CRC can be divided into well, moderately and poorly differentiated
adenocarcinomas based on the histologic presence of glandular differentiation. By
definition CRC is classified as being poorly differentiated (or high grade) if more than
50% of the tumor is formed by non-gland forming neoplastic cells.2 Subtypes of poorly
differentiated CRCs include undifferentiated or medullary carcinomas (MC), signet ring
cell carcinomas (SRC), neuroendocrine carcinomas (NE) and poorly differentiated not
otherwise specified (PDC).2 Approximately 20% of all CRC fall into the poorly
differentiated category.3
A number of immunohistochemical and PCR markers specific for intestinal
epithelium have been characterized and their retention in many CRCs has been utilized
for the identification of metastatic tumors, detection of occult lymph node metastases and

for detecting circulating tumor cells in the peripheral blood.4-6 Guanylyl cyclase C (GCC)
is an N-linked glycoprotein receptor for heat stable enterotoxin that is expressed by
intestinal epithelium.7,8 The intestine specific expression of the GCC promoter requires
CDX2.9 GCC has been shown to be a sensitive and specific marker for CRCs, and its
expression is retained in the adenoma to adenocarcinoma sequence.10,11 Molecular studies
to detect the presence of GCC have been proposed as a method of detecting occult
micrometastases to regional lymph nodes in CRCs.12-15 To date, the expression of GCC in
poorly differentiated CRCs has not been thoroughly investigated.
CDX2 is a transcription factor expressed in intestinal epithelial cells and is
thought to play a role in the differentiation and proliferation of intestinal epithelium.16
Several studies have show CDX2 to be both a sensitive and specific marker of intestinal
differentiation; furthermore, it appears to be overexpressed in CRC tumor cells compared
with normal intestinal epithelium.17-19 While the majority of well and moderately
differentiated CRCs stain strongly for CDX2, certain studies have shown that a lower
proportion of poorly differentiated tumors express CDX2.20-21
The focus of this study was to examine the pattern of staining of GCC expression
in a large cohort of poorly differentiated CRCs and to correlate these findings with the
expression of CDX2.

Material and Methods
Patients and samples
Formalin-fixed paraffin embedded tissues from 72 specimens including 44 poorly
differentiated (PDC), 15 undifferentiated or medullary (MC), 10 signet ring cell (SRC)

and 3 neuroendocrine (NE) CRCs were collected from the archives of the Department of
Pathology at the Rhode Island and Miriam Hospitals in accordance with Institutional
Review Board approvals from both hospitals. The written reports of all colon cancer
patients diagnosed between the years 1984-2008 were reviewed and all cases classified as
PDC, MC, SRC and NE were selected . Histological sections were reviewed by MR and
BW and were reclassified based on the current WHO criteria.2

Tissue microarray construction
Areas of pure invasive carcinoma were identified on hematoxylin-eosin-stained
slides from each case. In cases of PDC that showed focal well differentiated areas, only
the poorly differentiated components were selected. The corresponding areas on the
paraffin embedded source blocks were identified and marked. The source blocks were
then cored and a 1-mm core was transferred to the “master block” using the Beecher
Tissue Microarrayer (Beecher Instruments, Silver Spring, MD). Approximately three to
five tissue cores of tumor were obtained for each case. Additionally, two to three cores
of histologically normal adjacent colonic mucosal tissue were obtained and arrayed in the
same manner. Whole sections of five cases of PDC which had focal well differentiated
areas were also assessed. In addition a tissue microarray (TMA) constructed previously
containing 111 cases of primarily moderately to well differentiated CRC was assessed.22

Immunohistochemistry
Immunohistochemical staining for each antigen was performed on 6 micron
paraffin sections of each of the TMA masterblocks. The TMA sections were stained for

CDX2 (mouse antibody, clone CDX2-88, 1:50, Biogenex, San Ramon, CA) and GCC
(rabbit polyclonal, Gift from SA Waldman, first described by Birbe et al11) were
performed using the Dako Autostainer with the Dako Envision Plus kit or manually with
the Dako Envision Plus kit. The slides were counter stained with hematoxylin and
dehydrated in graded alcohols through to xylene and coverslipped. Normal colonic
mucosa served as a positive control both CDX2 and GCC.

Immunohistochemical assessment
The immunohistochemical stains were scored using a two-tiered scoring system:
positive or negative. A positive score required moderate to strong staining of more than
10% of the tumor cell population, whereas a negative score included tumors with focal
(less than 10%) or weak staining.. This cutoff was reached based on personal experience
and allowed for minimal interobserver variability in the scoring. BW and MR
independently scored each of the sections without knowledge of the histologic diagnosis
or staining pattern with the other marker. There was a high correlation between the two
scores and in the few discrepant cases, a consensus was reached after joint review.

Statistical analysis
Staining for GCC and CDX2 was compared between well differentiated CRCs
and PDC, MC, SRC and NE using Fischer’s exact test. Correlation between GCC
staining and CDX2 staining and the clinicopathologic comparison of MC and PDC was
also analyzed using Fischer’s exact test. Two-tailed P values of 0.05 or less were
considered to be statistically significant.

Results
The clinicopathologic characteristics of the 72 cases of CRC are summarized in
Table 1. The MC group had the highest mean age at the time of surgery (76yrs) as
compared to the SRC, PDC and NE groups which were 71yrs, 68yrs and 62yrs
respectively. The majority of patients with MC (87%), SRC (80%) and NE (67%) were
female whereas only 45% of patients with PDC were female. The majority of tumors
occurred on the right side in the MC (73%), SRC (80%) and NE (67%) groups whereas
PDC was right sided in only 45% of cases.
An example of each of the tumor types studied, PDC, MC, SRC and NE is shown
in Figure 1. MC lacked glandular differentiation and exhibited solid sheets of neoplastic
cells with a syncytial growth pattern and a moderate amount of eosinophilic cytoplasm.
An intra-tumoral and peri-tumoral lymphocytic infiltrate was present. The PDC tumors
were composed of at least 50% solid sheets or single neoplastic cells. Typically the
tumor cells were more pleomorphic than the MC group. SRC were composed of at least
50% of cells with prominent cytoplasmic mucin and characteristic displacement of the
nucleus. NE exhibited a typical neuroendocrine H&E appearance in combination with
strong positivity for at least one neuroendocrine marker.
The normal colonic epithelium served as a positive control for GCC and showed
typical apical membranous staining in all cases examined (Figure 2A). GCC stained the
apical luminal membrane of the tumor cells in the well to moderately differentiated
tumors (Figure 2B), whereas a predominantly cytoplasmic staining pattern was seen in
the more poorly differentiated areas, which was most pronounced in the MC group

(Figure 2C, 2D). The SRC tumors exhibited a cytoplasmic with focal membranous
staining (Figure 2E). NE tumors showed cytoplasmic and membranous staining (Figure
2F). The pattern of CDX2 staining was nuclear in both the tumor cells and the normal
colonic epithelium.
Out of the 72 tumor samples 75%, 47%, 90% and 67% of the PDC, MC, SRC and
NE tumors were positive for GCC and 75%, 40%, 90% and 100% of these subsets were
positive for CDX2 (Table 2). In contrast all but two of the 111 moderately to well
differentiated cases examined stained strongly for both GCC and CDX2. There was
excellent correlation between GCC and CDX2 expression on a case per case basis
(p<0.0001). GCC staining was more commonly lost in MC as compared to PDC
(p=0.025). Several separately stained whole sections from five tumors showing areas of
both well and poorly differentiated components were also examined. Positive GCC
staining in the well-differentiated component and negative staining in the poorly
differentiated areas was seen in these cases as depicted in Figure 3.

Discussion
GCC has been shown to be both a specific and sensitive marker of intestinal
differentiation and is being investigated as a biomarker for occult lymph node metastases
and circulating peripheral tumor cells.10-15 While essentially all well or moderately
differentiated CRCs have been shown to stain positively with GCC there is only limited
data on expression of GCC in PDC.10,11,14 Birbe et al. showed positive GCC staining in
10 out of 10 PDC and 5 of 5 SRC and Buc et al. showed 5 out of 5 PDC stained with
GCC.10,11 In contrast to the studies described above our study included a larger cohort of

PDCs and also included the specific poorly differentiated subtypes: MC, SRC and NE.
Our results indicate that a significant percentage of PDC (25%) and MC (53%) are
negative for GCC expression as compared to well differentiated CRC. Interestingly, 90%
of the SRC cases stained for both markers. There was also a strong positive correlation
between CDX2 and GCC expression. This was not surprising as intestinal GCC
expression requires a CDX2 binding element in the proximal promoter of CDX2.9
One of the most important factors in guiding treatment in patients with colorectal
carcinoma is regional lymph node metastases.23 Detection of micrometastases has import
clinical implications and may lead to more aggressive chemotherapeutic treatment;
however traditional techniques may fail to detect a significant proportion of lymph node
metastases in CRC and lead to under-staging.24,25 Several studies have demonstrated the
effectiveness of molecular studies using reverse transcriptase PCR for GCC in detecting
occult micrometastases to lymph nodes in CRCs.12-15 Schulz et al. showed quantitative
RT-PCR could be employed as a highly sensitive and specific method of detecting lymph
node metastases.14 Carrithers et al also showed that by reverse transcriptase PCR GCC
was present in peripheral blood samples of all patients with metastatic colorectal cancer
and none of the control group and that the presence of GCC in peripheral blood samples
may correlate with increased risk of recurrence or poorer prognosis.15 Bustin et al found
that only 1/21 healthy patients had reverse transcriptase PCR positivity for GCC in the
peripheral blood while 20/27 peri-operative patients with CRC were positive. In the same
study CK19 and CK20, two markers typically positive in CRC, were found to be
unreliable as indicators of circulating CRC tumors cells.6 Buc et al. also proposed GCC
as a potential target for delivering chemotherapeutic agents directly to tumor cells by

binding heat stable enterotoxin to an chemotherapeutic protein with subsequent GCC
dependant tumor cell uptake.10
Our findings suggest that if the primary CRC is poorly differentiated, there is a
significant chance that the lesion would not express GCC and thus metastases to lymph
nodes or circulating tumor cells in the peripheral blood may not be detected by molecular
methods. This would also be of significance if future modalities utilize GCC as a target
for delivery of proteins directly to tumor cells for imaging or chemotherapeutic purposes,
as PDC or poorly differentiated components of well differentiated CRC might not express
GCC.
Finally, the observation that a significant portion of these PDCs and poorly differentiated
components of well or moderately differentiated CRCs may lack staining with GCC is an
important consideration when using this immunohistochemical marker to aide in
determining the primary site in a metastatic carcinoma of unknown origin.
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Fig. 1. Hematoxylin and eosin stains of poorly differentiated adenocarcinoma (A),
medullary carcinoma (B), signet ring cell carcinoma (C) and neuroendocrine carcinoma
(D) (original magnification x200).

Fig. 2. GCC staining pattern in normal colonic mucosa (A), well differentiated
adenocarcinoma (B), poorly differentiated adenocarcinoma (C), medullary carcinoma
(D), signet ring cell carcinoma (E), and neuroendocrine carcinoma (F) (original
magnification x400).

Fig. 3. GCC staining in a whole section of tumor displaying both well differentiated
(right) and poorly differentiated areas (left) (original magnification x40).

